医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

KYOCERA Strengthens IoT Business Through Expansion of Software Laboratory

2016年03月22日 PM09:07
このエントリーをはてなブックマークに追加


 

KYOTO, Japan

Kyocera Corporation (NYSE:KYO)(TOKYO:6971) announced that it is promoting the acceleration and expansion of its Internet of Things (IoT) business. The company established its Software Laboratory in October 2015 which undertakes the mission of combining hardware and software technologies and enhancing value in the company’s diverse business fields including components for automotive, electronic and semiconductor applications, industrial cutting tools, printing devices and energy solutions. The Laboratory launched with a team of 20 employees and doubled to approximately 40 as of March 2016 with plans to further increase to around 200 by the FY2020 (fiscal year ending March 31, 2020).

Development Background

The IoT market continues to experience unprecedented growth with an estimated 26 billion devices to be linked to software by the year 2020*1. In Germany, the computerization of manufacturing has been promoted since the government’s Industry 4.0 action plan began in 2011. The U.S. is also making efforts toward developing IoT by establishing the Industrial Internet Consortium (IIC), which involves major electrical and electronic manufacturers, semiconductor firms and telecommunications equipment manufacturers. Japanese manufacturers have also been pursuing efforts to combine hardware technologies with software, expecting new business opportunities as a result of the proliferation of IoT.

Kyocera offers components and possesses element technologies in a wide range of areas including the automotive-related, communications, environment & energy, and medical & healthcare markets. In recent years, software technology is becoming increasingly important for the competitiveness of components in addition to miniaturization. Kyocera’s Software Laboratory undertakes tasks including strengthening R&D infrastructure for embedded software in its components businesses; enhancing the development capability of cutting-edge software technologies for equipment businesses; and creating new businesses by integrating components & devices, equipment & systems, and services.

In December 2015, the Software Laboratory adopted IBM® Bluemix (herein “Bluemix”), a Platform as a Service (PaaS)*2, which provides the database and infrastructure to create, deploy and manage applications for the cloud. Bluemix has enabled Kyocera to improve its productivity in software development by sharing developed software on the platform with customer companies and also meet diverse needs for customization of existing services that Kyocera offers in the field of energy management.

“We aim to introduce IoT innovations by combining Kyocera’s hardware technologies with the new developments from our Software Laboratory,” said Kazumi Saburi, General Manager of Kyocera’s Software R&D Group. “Spanning several decades, we’ve supplied a diverse range of electronic components and devices to industrial fields ranging from automotive and information/communication to environmental and energy engineering and healthcare. Our knowledge and experience in these markets allows Kyocera a unique perspective.”

IoT Business Development Areas

Automotive industry
Promote driverless assistance and pre-crash safety systems by utilizing image processing technology cultivated through camera module development.

Medical and healthcare services
Develop digital healthcare support systems, which when combined with guidance from healthcare professionals, manage physical conditions by sensing biological information including pulse, blood pressure, blood-glucose levels and body temperature.

Security and surveillance systems
Utilize IoT technology to process high-resolution video from surveillance cameras with the goal of improving crime prevention and safety monitoring to protect children and senior citizens.

Other equipment
Improve service quality including maintenance and failure prognostics by connecting Kyocera’s solar power generating systems or Kyocera Document Solutions’ printers and MFPs to IoT-optimized software.

*1: Based on information issued by Gartner, Inc. For details, please visit http://www.gartner.com/newsroom/id/2636073
*2: PaaS (Platform as a Service) is a model of global cloud computing services that provides a platform such as OS (Operating System) to deliver applications over the Internet.

IBM, the IBM logo, ibm.com, and Bluemix are trademarks of International Business Machines Corporation, registered in many jurisdictions worldwide. Other product and service names might be trademarks of IBM or other companies. For a current list of IBM trademarks, please visit http://www.ibm.com/legal/copytrade.shtml

About KYOCERA

Kyocera Corporation (NYSE:KYO)(TOKYO:6971) (http://global.kyocera.com/), the parent and global headquarters of the Kyocera Group, was founded in 1959 as a producer of fine ceramics (also known as “advanced ceramics”). By combining these engineered materials with metals and integrating them with other technologies, Kyocera has become a leading supplier of electronic components, semiconductor packages, solar power generating systems, mobile phones, printers, copiers, cutting tools, and industrial ceramics. During the year ended March 31, 2015, the company’s net sales totaled 1.53 trillion yen (approx. USD12.7 billion). Kyocera appears on the 2014 and 2015 listings of the “Top 100 Global Innovators” by Thomson Reuters, and is ranked #552 on Forbes magazine’s 2015 “Global 2000” listing of the world’s largest publicly traded companies.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160322005591/en/

CONTACT

KYOCERA Corporation (Japan)
Hina Morioka, +81-(0)75-604-3416
Corporate
Communications
webmaster.pressgl@kyocera.jp
Fax:
+81-(0)75-604-3516

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
  • ダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo SET®パルスオキシメトリーを使用するホームモニタリングの有用性を検討する新研究